Form 8-K - Current report:
SEC Accession No. 0001193125-26-202414
Filing Date
2026-05-04
Accepted
2026-05-04 06:18:17
Documents
13
Period of Report
2026-04-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d117008d8k.htm   iXBRL 8-K 53671
2 EX-99.1 d117008dex991.htm EX-99.1 14611
6 GRAPHIC g117008g0503064716395.jpg GRAPHIC 3820
  Complete submission text file 0001193125-26-202414.txt   203534

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aura-20260429.xsd EX-101.SCH 3188
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aura-20260429_lab.xml EX-101.LAB 17975
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aura-20260429_pre.xml EX-101.PRE 11263
16 EXTRACTED XBRL INSTANCE DOCUMENT d117008d8k_htm.xml XML 3624
Mailing Address 80 GUEST STREET BOSTON MA 02135
Business Address 80 GUEST STREET BOSTON MA 02135 (617)500-8864
Aura Biosciences, Inc. (Filer) CIK: 0001501796 (see all company filings)

EIN.: 320271970 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40971 | Film No.: 26934542
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)